---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-003071"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:33:58.132503+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma files IND for flu drug TXM; ratutrelvir beats Paxlovid on symptom resolution in interim study

## Summary
- IND filed with FDA for tivoxavir marboxil (TXM) for influenza; final step for BARDA stockpile consideration.
- Interim Phase 2 data: ratutrelvir showed faster symptom resolution vs Paxlovid (12 vs 14 days, p<0.014).
- No viral rebound in ratutrelvir arm vs one in Paxlovid; fewer adverse events (7.6% mild dyspepsia vs 30% in comparator).
- Ratutrelvir showed consistent safety and efficacy in Paxlovid-ineligible patients (13 patients).
- Full study enrollment expected in January 2026; 95% of 90 patients enrolled.

## SEC filing metadata
- accession: 0001104659-26-003071
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465926003071/0001104659-26-003071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465926003071/tm263039d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-003071
- JSON: https://secwatch.observer/filing/0001104659-26-003071.json
- Plain text: https://secwatch.observer/filing/0001104659-26-003071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.